The apparently higher sensitivity to ALK inhibitors of ALCL and IMT tumors likely reflects a stronger dependency on ALK signaling and/or a lower level of tumor heterogeneity than in ALK-rearranged NSCLC [17,18,19]. The gene discussed is ALK; the disease is neoplasm.